Article citationsMore>>

Alvarez, C., Alonso-Muriel, I., García, G., Crespo, J., Bellver, J., Simón, C. and Pellicer, A. (2007) Implantation is Apparently Unaffected by the Dopamine Agonist Cabergoline When Administered to Prevent Ovarian Hyperstimulation Syndrome in Women Undergoing Assisted Reproduction Treatment: A Pilot Study. Human Reproduction, 22, 3210-3214.
http://dx.doi.org/10.1093/humrep/dem315

has been cited by the following article:

• TITLE: The Importance of Prolactin Levels in Patients Treated with Cabergoline for the Prevention of OHSS: Is Cabergoline Really Effective in Patients with High Risk of OHSS?

  AUTHORS: Serkan Oral, Yaşam Kemal Akpak, Nilay Karaca, Kadir Savan

  KEYWORDS: Cabergoline, Ovarian Hyperstimulation Syndrome (OHSS), Prolactine Levels, In Vitro Fertilization (IVF), Vascular Endothelial Growth Factor (VEGF)

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.5 No.6, June 23, 2015

  ABSTRACT: Background: OHSS is a dangerous and potentially life-threatening condition for which many researchers look for new ways to treat. Aim: To determine the effectiveness of prophylactic cabergoline administration on prolactine levels in patients with high risk for ovarian hyperstimulation syndrome (OHSS). Material and Methods: 163 in vitro fertilisation (IVF) patients with high risk for OHSS were enrolled in the study. The criteria for inclusion were more than 15 oocytes retrieved at oocyte pick up. A standard antagonist protocol was used for ovulation induction. Cabergoline treatments (0.5 mg/day) were started on the day of oocyte retrieval and continued for eight days. Prolactine levels were measured at the day of oocyte retrieval and the 9th day after the oocyte retrieval. Results: Of the 163 patients, 26 (15.9%) had OHSS. Prolactine levels on the day of oocyte retrieval were 44.22 ± 24.78 ng/mL and 37.6 ± 22.5 ng/mL in patients with OHSS and without OHSS, respectively (P > 0.05). In contrary prolactine levels were significantly higher in patients with OHSS patients (3.9 ± 5.07 ng/mL) than in patients without OHSS (2.1 ± 2.92 ng/mL) at the 9th day after oocyte retrieval (P